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The most common objective for response-adaptive clinical trials is to seek to
ensure that patients within a trial have a high chance of receiving the best treat-
ment available by altering the chance of allocation on the basis of accumulating
data. Approaches that yield good patient benefit properties suffer from lowpower
from a frequentist perspective when testing for a treatment difference at the end
of the study due to the high imbalance in treatment allocations. In this work
we develop an alternative pairwise test for treatment difference on the basis of
allocation probabilities of the covariate-adjusted response-adaptive randomiza-
tionwith forward-lookingGittins Index (CARA-FLGI) Rule for binary responses.
The performance of the novel test is evaluated in simulations for two-armed stud-
ies and then its applications to multiarmed studies are illustrated. The proposed
test has markedly improved power over the traditional Fisher exact test when
this class of nonmyopic response adaptation is used. We also find that the test’s
power is close to the power of a Fisher exact test under equal randomization.
KEYWORDS
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1 INTRODUCTION
Equal randomization (ER) between treatment arms is the
gold standard for any clinical trial (eg, Schulz, 1996), as
such a randomization schemewill give the trial the highest
power to detect a treatment difference (Pocock, 1979) under
certain assumptions. While the purpose of any trial is to
gain information about an experimental treatment, there
is also the ethical consideration of the patients in the trial,
and these two goals often conflict with one another. This
has triggered the development of adaptively randomized
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trial designs, where the probability of a patient receiving a
particular treatment is altered sequentially throughout the
trial based on previous patients’ responses in order to treat
subsequent patients on treatments that are believed to be
superior. The use of such adaptive randomization has long
been suggested for implementation in clinical trials for the
advantages in patient benefit it offers (eg, Rosenberger and
Lachin, 1993; Hu et al., 2006) and a vast methodological lit-
erature has been developed on the subject of how to update
this patient allocation rule (eg, Rosenberger and Lachin,
2016; Williamson et al., 2017; Mozgunov and Jaki, 2020).
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Multiarmed bandit models are the optimal idealized
solution (in terms of patient benefit) to response-adaptive
allocation (Gittins, 1979). While their original motivation
was within trials, they have found wide application out-
side of trials (eg, Vermorel and Mohri, 2005; Gittins et al.,
2011) but have, to our knowledge, not actually been used
in the clinical trials setting. One of the reasons is that both
the optimal solution and the computationally efficient
approximate solution, the Gittins Index Rule (Gittins,
1979), is deterministic. In the clinical trials setting, the
deterministic nature of the Gittins Index Rule for patient
allocation and the assumption of infinite sample size
are problematic due to the inherent risk of bias (Hard-
wick and Stout, 1991). Modifications of the Gittins Index
Rule have been developed to apply the classic multiarmed
bandit framework to deriving nearly optimal patient allo-
cation procedure in clinical trials using adaptive random-
ization (Villar et al., 2015; Williamson and Villar, 2020).
These modifications allow for randomization, consider
finite-sized trials, and cater for patient accrual in blocks
rather than individually. One particular modification of
note is known as the modified forward-looking Gittins
Index Rule (Villar et al., 2015), which offers the advantage
that patient allocation is no longer deterministic. Instead,
patient allocation is random according to an allocation
probability. This probability can be calculated exactly or
using MC simulations that themselves use the determin-
istic Gittins Index Rule.
Extending to adaptive randomization to adjust alloca-
tion probabilities according to covariates of patients is
an important step in the area of personalized medicine.
Adjusting for covariates or biomarkers not only allows
for higher levels of patient benefit within the trial, but
also for the targeting of experimental treatments to patient
groups that will see the most rewards when the treatment
is marketed. Villar and Rosenberger (2018) introduce a
method that allows covariate adjustment, using amodified
forward-looking Gittins Index Rule, henceforth referred
to as the covariate-adjusted response-adaptive random-
ization with forward-looking Gittins index (CARA-FLGI)
procedure.
Nonmyopic bandit-based procedures increase patient
benefit by looking forward a considerable way into future
patients’ allocations.Hence they donot have the shortcom-
ings associated with myopic procedures that only take into
account past information in the allocation of the present
patient, namely, that in the exploring versus exploiting
theory of allocation rules (Gittins et al., 2011), they do
not explore enough. Consequently, such myopic proce-
dures can settle too early on an inferior arm (Villar et al.,
2015; Smith and Villar, 2018). Like all response-adaptive
designs, they have the drawback that the resulting designs
often lack in power due to substantial imbalance between
patient groups.
The purpose of most response-adaptive trials is to iden-
tify superior treatments quickly, and in doing so, the result-
ing patient allocation favors the superior treatment. When
directly performing inference on the binary responses of
the patients to determine the outcome of the trial, there
must be a trade-off between patient benefit and power.
For a two-armed trial (under equipoise and equal variance
assumptions), the closer the allocation is to equal sample
size in each group, the higher the power but smaller the
patient benefit. Likewise the further from equal the sample
sizes between treatments can be, the larger the potential
patient benefit but lower the power. Bandit-based designs
provide high patient benefit, and therefore suffer from
low power, which is a concern for their implementation
(Villar et al., 2015). Previous work on response-adaptive
randomization (RAR) has almost exclusively focused on
the question of design while using traditional approaches
for inference (eg, contingency table based for binary out-
comes). In this work we develop an entirely novel perspec-
tive on the analysis of such trials. The idea is based on
the observations that for bandit-based designs, when the
patient allocation favors a treatment, this is an indication
of the superiority of that treatment. It is therefore intuitive
to use this indication to analyze results from a trial uti-
lizing an FLGI procedure. In this paper we discuss how
testing based on allocation probabilities from the CARA-
FLGI procedure can be used as an alternative to testing
based on the binary outcome of response to test the null
hypothesis of no treatment effect difference. Alternative
approaches to inference that are tailored to the specific
RARalgorithm, such as the randomization test (Simon and
Simon, 2011) have been applied to the FLGI design (Vil-
lar et al., 2018). Such an approach preserves type I error
under broad assumptions but results in substantial power
loss when compared to traditional inference in a fixed ran-
domization trial. Motivated by the potential for a higher
powered response-adaptive randomized trial due to the
completely different nature of the sufficient statistics for
the test (the test statistic being a function of allocation
probabilities, which require the partial sums of successes
and failures on each of the treatment arms after each block
rather than the summary of these binary responses on each
of the treatment arms at the end of the trial), this novel
approach to decision making expands the potential of use
for alternative methodologies in adaptive randomization.
Our proposedmethodology is exactly the solution to one of
the key concerns posed in theNational Science Foundation
2019 report, Statistics at a Crossroads: Who Is for the Chal-
lenge?, stating “A fundamental issue is the development of
inference methods for post subgroup selection” (He et al.,
2019).
In the following, Section 2 provides a review of the
CARA-FLGI method, in particular how the allocation
probabilities are calculated. Section 3 derives the testing
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procedure for the use of the allocation probabilities in such
a trial. Section 4 then illustrates the use of the testing proce-
dure in both a realmultiarm trial scenario and simulations.
Alongside this, its comparative properties and advantages
over alternativemethods are presented beforewe conclude
with a discussion in Section 5.
2 PROPERTIES OF ALLOCATION
PROBABILITIES
2.1 The CARA-FLGI procedure
Throughout this paper, it is assumed that the CARA-FLGI
procedure, as described by Villar and Rosenberger (2018),
is applied. It is worth noting that although in the fol-
lowing we focus on the covariate-adjusted case, where
there are multiple biomarker categories that partition the
patient population labeled 𝑧 = 1,…𝑛𝑧 < ∞, the procedure
of using allocation probabilities for inference purposes as
we describe can indeed be applied to any FLGI alloca-
tion such as those presented by Villar et al. (2015); this
is a strong advantage of the procedure. In fact, since the
CARA-FLGI procedure reduces to the simpler FLGI allo-
cation when there is only a single biomarker category,
we also evaluate this case in the following work. It is
worth strongly emphasizing that what we propose here is
a novel testing procedure for a class of response-adaptive
designs, not a novel response-adaptive design itself. The
testing procedure can be used when interested in compar-
ing an experimental arm (possibly out ofmany) to a control
arm.
The trial set-up is as follows. Patients are accrued in
blocks of prespecified size 𝐵, with total trial sample size
𝑁 = 𝐾𝐵, where 𝐾 is the number of blocks. Biomarker cat-
egories that partition the patient population are defined,
and each patient has an associated biomarker category.
At the beginning of each block, an allocation probability
is calculated for each biomarker category using the FLGI
rule. This allocation probability is then used as the prob-
ability of assigning a patient within that biomarker cate-
gory to the experimental treatment. This differs from using
the standard Gittins Index Rule, as there is still random-
ness in the patient allocation. The larger the block size, the
higher the randomization element, although this comes
at the expense of deviating further from the optimality of
patient benefit and computational cost. We consider the
null hypothesis to be tested as 𝐻0 ∶ No treatment effect
difference in subgroup 𝑧, against the one-sided alternative
𝐻𝐴: The experimental treatment is superior to the control
in subgroup 𝑧.
Note that extensions to two-sided tests are straightfor-
ward. Traditionally, frequentist inference is carried out
using statistical tests that are based on the observed suc-
cess/failure outcomes from the trial. We propose how-
ever, to use the CARA-FLGI allocation probabilities cal-
culated at the beginning of each block to test these
hypotheses. In the following, we provide an overview of
how these probabilities are calculated using the FLGI in
order to understand why they can be used for testing the
hypotheses.
2.2 Calculation of CARA-FLGI
allocation probability distribution
At the beginning of every block in the trial, the CARA-
FLGI procedure calculates an allocation probability per
treatment arm, per biomarker category. This FLGI pro-
cedure can use allocation probabilities calculated exactly
(Villar et al., 2015), however the theoretical calculation is
extremely intensive and therefore Monte Carlo (MC) sim-
ulations are often used to calculate these probabilities. In
the following, we assume the use of MC simulations. For
simplicity, we here assume that there are two treatment
arms, labeled 0 for control and 1 for experimental, although
the calculations are identical if multiple treatment arms
are used. Let us recap how the procedure calculates the
allocation probability for the experimental treatment for
biomarker category 𝑧, 𝑝alpro,z, using MC simulations. It is
worth noting that the following calculations are neither
under the null nor alternative hypotheses as there is no
assumption on treatment difference when calculating the
probabilities themselves.
First, consider the current states of all biomarker cate-
gories at the beginning of the block, which are defined by
the number of successes on the standard treatment (𝑠0,𝑧),
failures on the standard treatment (𝑓0,𝑧), successes on the
experimental treatment (𝑠1,𝑧), and failures on the experi-
mental treatment (𝑓1,𝑧). We denote the current state 𝑖 in
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). For the first block
in the trial, this state is specified via an uninformative
prior of 𝑆1𝑧(1, 1, 1, 1). Although we advise an uninforma-
tive prior, an informative prior may be used if appropriate,
provided the following distribution calculations are under
the assumption of the same prior as used in the trial. From
each of these category states, the procedure takes 𝑛 MC
runs labeled 𝑗 = 1,… , 𝑛; each run is an independent block
of the prespecified size 𝐵.
Within each MC run, 𝑗, the first patient is allocated to
one of the treatment arms and success/failure is observed.
The state for that biomarker category is updated, and the
next patient is allocated to a treatment arm based on their
(possibly updated) biomarker category state. This contin-
ues until the block is full, noting that patients in the same
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block may have different biomarker categories. This is
repeated for each run, starting at the same initial states for
each category.
The allocation of patients in the FLGI allocation proce-
dure (and therefore in theMC simulations) depends on the
Gittins Index (𝐺𝐼) Rule (Gittins, 1979). For a given patient,
this rule takes the two available treatment arms (standard
and experimental for the patient’s biomarker category) and
calculates the 𝐺𝐼 for each arm. The patient is allocated to
the treatment armwith the highest𝐺𝐼, breaking ties at ran-
dom. At any given point, and consistent with the multi-
armed bandit framework, we assume that patient success
for a given treatment arm occurs according to the poste-
rior success probability so far on that treatment arm.When
FLGI probabilities are estimated through an MC proce-
dure, the allocation probability for each category is the pro-
portion of patients in each category allocated to the exper-
imental treatment over the total number of runs.
This allocation probability is calculated (or approx-





𝑋𝑗,𝑧. Assuming that every biomarker cate-




) is the number of patients belonging to
biomarker category 𝑧 (regardless of treatment) in the 𝑗th
MC run, equalling 𝐵 when 𝑛𝑧 = 1, and 𝑌𝑗,𝑧 is the number
of patients in category 𝑧 allocated to the experimental
treatment on the 𝑗th MC run. For simplicity but with no
loss of generality we assume 𝑃(𝑍 = 𝑧) = 1∕𝑛𝑧.
In order to calculate the distribution of 𝑝alpro,z, we con-
sider the cumulative distribution function
𝐹𝑝alpro,𝑧(𝑐) = ℙ(𝑝alpro,z ≤ 𝑐)




















Note that this assumes
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𝑋𝑗,𝑧 = 0), then the allocation probability
is taken as 0.
The derivation of the discrete joint distribution of 𝑋𝑗,𝑧
and 𝑌𝑗,𝑧 is provided in Web Appendix B in the online sup-
porting information. For a given 𝑗, let the expectations
be denoted as 𝔼(𝑋𝑗,𝑧) = 𝜇𝑥,𝑧 and 𝔼(𝑌𝑗,𝑧) = 𝜇𝑦,𝑧. and vari-
ances Var(𝑋𝑗,𝑧) = 𝜎2𝑥,𝑧 and Var(𝑌𝑗,𝑧) = 𝜎2𝑥,𝑧. The covari-




𝑃(𝑋𝑗,𝑧 = 𝑥𝑗,𝑧&𝑌𝑗,𝑧 = 𝑦𝑗,𝑧)
× (𝑥𝑗,𝑧 − 𝜇𝑥,𝑧)(𝑦𝑗,𝑧 − 𝜇𝑦,𝑧)
where the sum is over all possible values of 𝑥𝑗,𝑧 and 𝑦𝑗,𝑧.











We approximate the following using the Central Limit
Theorem for the MC runs:
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Thus the distribution has a mode at 𝜇𝑦,𝑧∕𝜇𝑥,𝑧. For a







), this is the ratio
of the expected number of patients allocated to the exper-
imental treatment in subgroup 𝑧 compared to the total
expected number of patients in subgroup 𝑧.
3 TESTING FOR SUPERIORITYWITH
ALLOCATION PROBABILITIES
We present the following theorem for testing for superior-
ity using allocation probabilities.
Theorem 3.1. Denote the true difference in success proba-
bility on the experimental treatment and control by 𝑝1 − 𝑝0.
Consistently higher allocation probabilities for the exper-
imental treatment, that is, more allocation probabilities
greater than 0.5 at beginning of blocks within the trial, are
observed if and only if 𝑝1 − 𝑝0 > 0.
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The theorem is a direct result of the following two lem-
mas, the proofs of which are given in Web Appendix C in
the online supporting information.
















) will give ℙ(𝑝alpro,z > 0.5) = 𝛾.
Lemma 3.2. Consistently higher allocation probabilities for
arm 1 are a necessary and sufficient condition for 𝑝1 − 𝑝0 >
0.
In order to use the allocation probabilities to test for
superiority, we utilize the distribution of the allocation
probabilities under the assumption that the treatment
effects are equal (null distribution). The distribution of
the allocation probability for a given block described by
Equations (1) and (2) is calculated solely from the state
at which that block starts. The success probabilities used
in the CARA-FLGI are the posterior probabilities within
the simulation, and not under any assumptions on the
treatments themselves. However, the full null distribu-
tion of allocation probabilities for any block, 𝑘, is under
the assumption that the treatment effects are equal. This
distribution is a mixture distribution; a weighted sum of
the allocation probability distributions 𝑓𝑝alpro,𝜁,𝑧 from the
potential states 𝜁, of which there are say 𝑍, at the
beginning of block 𝑘, with weights of probabilities of
being in each of the potential states ℙ𝑧(𝜁), for a given
equal success probability for both treatments: 𝑔(𝑘)(𝑐) =∑𝑍
𝜁=1
𝑓𝑝alpro,𝜁,𝑧(𝑐)ℙ𝑧(𝜁). This mixture distribution has
point masses at 0 and 1, as for certain extreme states, the
probability of allocating a patient to the experimental treat-
ment is either 0 or 1. As this can occur fairly frequently, the
resulting distribution can often not be used to formulate a
nonrandomized level-𝛼-test (see Fig. 3 in Smith and Villar,
2018, for a similar issue in a different setting). To overcome
this bimodality problem we instead consider the number
of blocks for which the allocation probability exceeds 0.5.
To achieve this, the allocation probabilities are
dichotomized according to whether they are greater
than 0.5. We then denote the binary outcome 𝛼𝑘 as 1 if the
allocation probability to the experimental arm for block




𝛼𝑘, is then the total number of blocks for which
the allocation probability to the experimental arm is larger
then 0.5. Note that the value of 0.5 is for the two-arm
setting. For a trial withmultiple arms, this is the reciprocal
of the number of arms.
The discrete distribution of 𝑄 under the assumption of
no treatment difference is given inWeb Appendix D in the
online supporting information. Using this distribution we
can then find the critical value as the smallest value 𝑐𝑞 that
satisfies 𝑃(𝑄 > 𝑐𝑞|𝑝0 = 𝑝1) < 𝛼 and reject the null hypoth-
esis if 𝑄 > 𝑐𝑞 as usual. Note that for larger sample sizes,
the calculation of the exact distribution is computationally
intensive and it may be more useful in practice to estimate
the distribution via MC simulation. The leftmost plot in
Figure 1 shows the null distribution of 𝑄 for a total sam-
ple size of 20, split into 10 blocks of size 2, for 𝑛𝑧 = 2. The
distribution is symmetric about the midpoint of 5 due to
the assumption that treatments have equal success proba-
bilities. In this example distribution, the probability of see-
ing 10 blocks eachwith allocation probability to the experi-
mental above 0.5 is 0.043. Hence in order to conclude there
is evidence to suggest the experimental treatment is supe-
rior at the 5% level, we must observe more than nine allo-
cation probabilities greater than 0.5. For such a test, the
power is not adversely affected by the imbalance in treat-
ment groups, in fact the power increases for larger imbal-
ances.Abigger underlying treatment difference givesmore
skewed allocation probabilities, which means more imbal-
ance between groups (see Figure 1). When performing tra-
ditional inference on the outcomes of the trial, for exam-
ple, using a Fisher exact test, the assumptions required for
the validity of the test are violated by the heavy dependen-
cies on the outcomes and sampling direction. Therefore,
the increase in power from a larger treatment difference is
lessened by the imbalance in treatment groups. When test-
ing using the allocation probabilities as described above,
this is not the case. We have constructed a test that has
a structural property of the design embedded into it and
therefore better aligns to the properties of the experiment
underlying it. This highlights the key advantage to the pro-
posed inference approach—no assumptions of the statisti-
cal test are violated by an imbalance in treatment groups
because the test statistic 𝑄 is constructed in a framework
that supports this imbalance.
4 APPLICATION
4.1 Simulations
In order to compare the use of tests based on allocation
probabilities versus those based on success rates, we com-
pare and evaluate the performance with simulated data
sets. Since we envisage that the main advantage of using
allocation probabilities is to increase the power of the test
for superiority, we compare the power for treatments with
varying success probabilities in simulated two-arm trials
that implement the CARA-FLGI procedure.
We compare the results from the proposed procedure to
two other inference methods for trials using the CARA-
FLGI. These analyze the results using (a) a Fisher exact test
of success rates and (b) a Generalised LinearModel (GLM)
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F IGURE 1 An illustration of the null distribution and two alternative distributions of 𝑄, the total number of blocks for which the
allocation probability to the experimental arm is greater than 0.5, for 𝐾 = 10, 𝐵 = 2 and 𝑛𝑧 = 2
with 𝑙𝑜𝑔𝑖𝑡 link function (𝑙𝑜𝑔𝑖𝑡(𝜌𝑧) = 𝛽0 + 𝛽1𝑇, where 𝜌𝑧 is
the success rate for biomarker category 𝑧 and 𝑇 is an indi-
cator variable taking the value 1 if a patient is assigned
to the experimental treatment). The robust alternatives
of randomization tests are not compared since they have
already been shown to be inferior to the Fisher exact test in
terms of power (Villar et al., 2018) in this class of designs.
The only comparison we use to an alternative allocation
rule is using ER between the arms and analyzing results
using a Fisher exact test on success rates. These trials will
have sufficient power, but much smaller patient benefit
than those using adaptive randomization and hence are
used as a benchmark in terms of power. We have inten-
tionally not included comparisons to alternative CARA
designs, since our objective is to improve the power of a
particular class of designs by using a novel testing proce-
dure, not to introduce a novel adaptive design. We refer
the interested reader to Villar and Rosenberger (2018) for
a detailed simulation study comparing the CARA-FLGI
to other CARA designs. We also report the percentage of
patients on the best treatment, and the total number of
observed successes in order to highlight the patient benefit
of the CARA-FLGI.
Trials of three different sample sizes are considered,𝑁 =
40, 80, 160. For the CARA-FLGI procedure, a block size of
𝐵 = 2 is used initially with an extension to𝐵 = 4 and𝐵 = 8
to assess the impact of block size. For the use of allocation
probabilities, the first two blocks’ allocation probabilities
are disregarded as a run-in for the CARA-FLGI proce-
dure so that the allocation probabilities used in the test-
ing procedure are meaningful and can be interpreted. In
all cases presented here, we use a run-in of two blocks,
chosen to maintain power. In practice this run-in can be
tailored to suit the expected operating characteristics of
the trial, in which case we would recommend at least two
and no more than 10% of 𝐾, the total number of blocks.
It must be noted that the run-in is for inference only, the
sample size includes those patients in the blocks whose
allocation probabilities are disregarded. For each sample
size, the number of biomarker categories considered are
𝑛𝑧 = 1, 2, 3, 4.
As it is known that the Fisher exact test can lead to a
conservative type I error rate (eg, Storer andKim, 1990), we
adjust the rejection criteria in each case to ensure that a 5%
type I error rate is observed in the simulations in order for
a fair comparison between methods. For the Fisher exact
test and GLM, this is implemented by simply adjusting
the critical value for rejection. For the test using allocation
probabilities, we use a randomized test. Results that are
unadjusted for type I error rate are given inWeb Appendix
A in the online supporting information, which also show
that the proposed procedure controls the type I error rate
before adjustment in almost all cases. Where this is not the
case with smaller 𝑁 and larger 𝑛𝑧, this is due to the null
distribution of 𝑄 having slightly heavier tails. The infla-
tion will be known in advance, and any necessary adjust-
ment can be made. The proposed procedure still shows
higher power, even when adjusted for. Figures 2–4 com-
pare the power across the 12 scenarios when type I error
is adjusted for. In each case, the success probability of the
control treatment is set to 0.5 and the success probability
of the experimental treatment increases along the 𝑥-axis.
Themost notable characteristic of all of these graphs is that
the power curve for the procedure using allocation prob-
abilities of the CARA-FLGI procedure closely follows the
curve for the Fisher exact test using success rates in the ER
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F IGURE 2 Comparison of power for 𝑁 = 40 & 𝐵 = 2; rejection criteria adjusted for type I error rate
design. At the same time the power of the test based on
allocation probability is markedly higher than the Fisher
exact test and the logistic model when the CARA-FLGI
procedure is used to allocate patients.
The power of the test using allocation probabilities is
minimally affected by an increase in the number of cate-
gories for the larger sample sizes, whereas the power of the
Fisher exact test is adversely affected by an increase in cat-
egories. For the scenarios with four biomarker categories,
the difference between the Fisher exact test applied to the
equal allocation simulations and the use of allocation prob-
abilities applied to the simulations using the CARA-FLGI
procedure is atmost 20%.Whereas the gain of using alloca-
tion probabilities as opposed to the Fisher exact test when
the CARA-FLGI is used to allocate patients is up to 40%
for the larger sample sizes. The smaller the sample size,
the closer the power of the Fisher exact test applied to the
equal allocation simulations and the use of allocation prob-
abilities applied to the simulations using the CARA-FLGI
procedure. Any difference in power is only noticeable in
the case of one biomarker category.
When considering the effect of varying block sizes on
the power of the procedure, a comparison between the
proposed method using allocation probabilities to test for
treatment difference and the Fisher exact test on success
rates using FLGI randomization is presented in Figure 4
in Web Appendix A in the online supporting information.
For larger numbers of categories, the power of the pro-
posed method is well maintained. However, the power
is adversely affected for increasing block size when only
one category is considered; there is a clear relationship
between both the number of categories and block size.
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F IGURE 3 Comparison of power for 𝑁 = 80 & 𝐵 = 2; rejection criteria adjusted for type I error rate
Although the power of the Fisher exact test on success rates
increases for larger block sizes due to the increased bal-
ance between treatment groups (and hence lesser patient
benefit), it still does not achieve the power of the proposed
procedure with 𝐵 = 2. A larger block size may be advanta-
geous in a trial for practical reasons, but both the largest
patient benefit and highest power are achieved using the
proposed procedure and a smaller block size. If a larger
block size is required, in order to maintain power and
patient benefit we recommend 𝐵 ≤ 𝑛𝑧 + 1. In relation to
this, we also recommend a minimum number of blocks of
𝐾 ≥ 20.
These results are especially promisingwhen considering
the amount of patient benefit that the adaptive randomiza-
tion offers. Tables 1 and 2 show the percentage of patients
that were on the correct treatment across the simulations,
for a true underlying treatment difference of 20% and 30%,
TABLE 1 Percentage of patients on the correct treatment, and
average total observed successes using CARA-FLGI with 𝐵 = 2
compared with equal randomization (ER). True treatment
difference of 20%
Patients on correct treatment
CARA -FLGI ER
𝒏𝒛 = 1 𝒏𝒛 = 2 𝒏𝒛 = 3 𝒏𝒛 = 4 –
N = 40 77% 71% 67% 65% 50%
N = 80 85% 78% 74% 72% 50%
N = 160 90% 84% 81% 78% 50%
Average total successes
CARA-FLGI ER
𝒏𝒛 = 1 𝒏𝒛 = 2 𝒏𝒛 = 3 𝒏𝒛 = 4 –
N = 40 26 26 25 25 24
N = 80 53 52 52 51 48
N = 160 109 107 106 105 96
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F IGURE 4 Comparison of power for 𝑁 = 160 & 𝐵 = 2; rejection criteria adjusted for type I error rate
TABLE 2 Percentage of patients on the correct treatment, and
average total observed successes using CARA-FLGI with 𝐵 = 2
compared with equal randomization (ER). True treatment
difference of 30%
Patients on correct treatment
CARA -FLGI ER
𝒏𝒛 = 1 𝒏𝒛 = 2 𝒏𝒛 = 3 𝒏𝒛 = 4 –
N = 40 86% 80% 76% 73% 50%
N = 80 92% 87% 84% 81% 50%
N = 160 96% 93% 90% 88% 50%
Average total successes
CARA -FLGI ER
𝒏𝒛 = 1 𝒏𝒛 = 2 𝒏𝒛 = 3 𝒏𝒛 = 4 –
N = 40 30 30 29 29 26
N =80 62 61 60 59 52
N = 160 126 124 123 122 104
showing a stark improvement of CARA-FLGI over ER.
The tables also show the average total number of successes
per trial. Again, there are unsurprisingly far more suc-
cesses observed for the adaptive design than for ER. For
example, for a treatment difference of 20% and𝑁 = 40, ER
gives the average total number of successes of 24. However,
with such a small treatment difference, even if all patients
were allocated to the superior treatment, this would be
28 and the CARA-FLGI has 26. The modest improvement
of patient success is reflective of the scenario and not
the CARA-FLGI approach. For a treatment difference
of 30%, the average total successes for ER for 𝑁 = 160 is
104, however, if all patients were allocated to the superior
treatment, this would be 128 and the CARA-FLGI has
126. The design gives substantial patient benefit over ER
and our proposed inference procedure gives comparable
power to ER for small block sizes in practice, a clear
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indication that the proposed procedure has the potential
for success.
4.2 Illustrative multiarm example
In order to demonstrate the use of FLGI allocation prob-
abilities to test for superiority in a multiarm setting, we
use the following trial reported by Attarian et al. (2014),
which looked at the a combination of baclofen, naltrexone,
and sorbitol (PXT3003) in patients with Charcot-Marie-
Tooth disease type 1A as an illustrative example. A total
of 80 patients were randomized to either the experimen-
tal treatment PXT3003 in three different doses, or a con-
trol group receiving a placebo. In this trial, ER was used,
with 19 patients randomized to the control group, and 21,
21, and 19 patients allocated to the low, intermediate, and
high doses of PXT3003, respectively. The aim of the study
was to assess both safety and tolerability as well as efficacy,
with themeasure of safety and tolerability of the total num-
ber of adverse events. In the placebo group, a total of 9 out
of 19 patients suffered adverse events, whereas this was 5,
7, and 6 in the low, intermediate, and high dose groups,
respectively.
We will use this example to simulate how this four-
armed trial with a single biomarker category would have
looked using the FLGI procedure with 𝐵 = 2, testing if
the allocation probability exceeds 25% across blocks 3 to
40. As there is only one category, we find the critical
value, 𝑐𝑞 to be 30. In this example, we consider only
pairwise comparisons between individual active treat-
ments and control each at full level 𝛼 for simplicity. Should
overall control of the family-wise error rate be desired,
standard approaches such as a Bonferroni correction or
similar adjustment (Simes, 1986) can be applied. Hence we
consider the pairwise tests defined by null hypotheses𝐻0𝑘
that there is no treatment effect difference between arm 𝑘
and the control arm, with alternative hypotheses 𝐻1𝑘 that
active treatment arm 𝑘 is superior to the control arm. We
therefore define power in this case as the marginal power,
the probability of correctly rejecting null hypothesis 𝐻0𝑘
for the treatment 𝑘 with the largest true treatment effect
difference from the control.
We will consider three scenarios of varying success rates
across the four arms in this illustration. In the first scenario
all treatments (including control) have the same success
rate of 0.5, while the second scenario uses the estimated
success rates from the study itself. The final situation con-
siders a linear dose–response relationship from 0.53 to 0.77
(the lowest to highest observed success rates in the trial)
across the four treatment arms.
In 10,000 replications of the trial under the null hypoth-
esis, the type I error rate was well controlled at 5% for
the procedure using FLGI allocation probabilities, but was
conservative for the Fisher exact test for both allocation
schemes. In the scenario, which mimicked the results of
the study (some difference between control and active,
but hardly any between the different doses), on average
38 patients were allocated to the active treatment with the
best underlying success rate and the average total num-
ber of successes was 56 compared to the 53 in the original
trial. In 34% of the simulations the null hypothesis could
be rejected using allocation probabilities compared to 32%
to using ER and Fisher exact test. In the final scenario
of a linear dose–response a similar trend was observed.
Using allocation probabilities to test for superiority led to
an increase in power to 41% from the 35%of theFisher exact
test applied to the observed successes in the trial with ER.
5 DISCUSSION
RAR can offer patient benefit, but in most cases at the
expense of power. In this paper we have introduced a
novel inference approach to analyze a clinical trial con-
ducted using an FLGI design, based on a unique per-
spective on the accumulated information, that does not
suffer from decreased power. By using the allocation prob-
abilities generated in the FLGI procedure as opposed to
the observed binary outcomes, we address the low power
associatedwith unequal sample sizes inherent in response-
adaptive designs.
Although in this paper we have shown promising results
for trials implementing the CARA-FLGI rule for patient
allocation, it is widely applicable in trials using any FLGI
rule. In fact, such is the generality of this novel approach
for inference that it can be applied (potentially in some
redefined way) to trials using other response-adaptive ran-
domized allocation rules such as the randomized play the
winner rule (Wei and Durham, 1978) and similar methods
where the allocation probabilities are updated on accumu-
lating patient responses. Our novel approach would not be
applicable in cases where a target is not revisited at inter-
ims, or is changed by allocations but not by responses, like
restricted randomization. We expect the approach to work
best when the underlying RAR deviates allocations signif-
icantly under the presence of a signal, like the FLGI.
A standard approach in response-adaptive multiarm tri-
als to overcome the low power is to preserve the sample
size of the control group (eg, Trippa et al., 2012; Villar et al.,
2015). This is either achieved by starting the trial with an
initial period of ER before applying RAR or simply having
a fixed allocation to the control arm throughout (although
the latter is not applicable in the two arm case, which this
novel testing approach is). Both of these dohowever reduce
the patient benefit. One additional advantage of the novel
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testing approach over such arbitrary rules is that testing
on the basis of allocation probabilities yields good power
without sacrificing the patient benefit of using RAR for the
entire study.
The only valid alternative approach to analyze clinical
trials with RAR is randomization-based inference (Simon
and Simon, 2011), which is known to be robust but reduce
power compared to naive approaches (see Villar et al.,
2018). Our approach is the first alternative to existingmeth-
ods to be tailor made to these designs that increases power
compared to such naive, and additionally not valid, analy-
sis options.
In this work we have focused our explorations to pair-
wise testing of two treatment groups. However, RAR is
known to perform well for trials with multiple arms
(Wason and Trippa, 2014). While we illustrate how a
pairwise testing strategy can be applied in this setting fur-
ther extensions to global tests in multiarmed trials are of
interest.
As is commonly the case in RAR, we assume here
that the previous block of patients’ responses are avail-
able before assignment of the next block; inherent in such
designs to increase the patient benefit. However, if desired,
both the CARA-FLGI procedure and our novel test may
be applied to a setting with delayed responses, subject to
minor modifications.
Finally, although focus here has been on superiority of a
treatment in a pairwise test, the procedure can be adapted
for two-sided tests by considering both tails of the null dis-
tribution.
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